monomethyl fumarate

November 29, 2017November 30, 2017

Alkermes, Biogen Partnering on Therapy for Relapsing Forms of Multiple Sclerosis

Alexa, News

Alkermes and Biogen have begun working together on a compound known as ALKS 8700 as a potential treatment for relapsing forms of multiple sclerosis. Under the agreement, Alkermes will be responsible ... Read more

November 1, 2017November 13, 2017

#MSParis2017 – EVOLVE-MS-1 Interim Trial Data Shows Alkermes Therapy Safe for Treating Relapsing MS

News

Preliminary data from the Phase 3 EVOLVE-MS-1 trial shows that ALKS 8700 — an investigative therapy developed by Alkermes to treat relapsing forms of multiple sclerosis — has a good ... Read more

October 20, 2017October 23, 2017

#MSParis2017 – Alkermes to Give Updates on ALKS 8700 Studies at ECTRIMS-ACTRIMS Meeting

News

Alkermes will showcase its work in developing a treatment that harnesses the effect of Tecfidera (dimethyl fumarate) for relapsing multiple sclerosis (MS), while lowering the risk ... Read more

March 20, 2017March 20, 2017

Alkermes Begins Phase 3 Study of ALKS 8700 as Relapsing MS Treatment

News

Alkermes has started a Phase 3 clinical trial evaluating ALKS 8700, the oral monomethyl fumarate (MMF) prodrug it is developing for the treatment of relapsing forms of ... Read more

December 18, 2015December 18, 2015

New MS Drug Therapy Based on Monomethyl Fumarate Moving Along in Testing

News

Alkermes plc, a biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, announced that it has successfully met its 2015 goals ... Read more

Pin It on Pinterest